Detection of intraductal carcinoma in prostate cancer patients with small tumor volume.
insignificant cancer
intraductal carcinoma
prostatectomy
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
16
11
2022
received:
05
02
2022
accepted:
23
01
2023
pubmed:
11
2
2023
medline:
25
3
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
The purpose of this study was to investigate intraductal carcinoma of the prostate (intraductal carcinoma) and significant cancer (SC) in patients with small tumor volume (<0.5 cm Data from 639 patients undergoing radical prostatectomy between April 2006 and December 2017 at Chiba University Hospital and 2 affiliated institutions were retrospectively reviewed. Tumor volume in prostatectomy specimens was measured, and with a tumor volume of less than 0.5 cm A total of 83 patients with tumor volume < 0.5 cm The results of the present study suggest that intraductal carcinoma was present even in cases with small tumor volumes. Grade Group and intraductal carcinoma showed a positive correlation with tumor volume.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
580-589Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/caac.21590
Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23(2):15. doi:10.1007/s11912-020-01003-9
Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532-2542. doi:10.1001/jama.2017.7248
Epstein JI. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-374.
Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71(3 suppl):933-938. doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l
Wolters T, Roobol MJ, van Leeuwen PJ, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol. 2011;185(1):121-125. doi:10.1016/j.juro.2010.08.082
Colarieti A, Thiruchelvam N, Barrett T. Evaluation of image-based prognostic parameters of post-prostatectomy urinary incontinence: a literature review. Int J Urol. 2021;28:890-897. doi:10.1111/iju.14609
Namiki S, Tochigi T, Kuwahara M, et al. Health related quality of life in Japanese men after radical prostatectomy or radiation therapy for localized prostate cancer. Int J Urol. 2004;11(8):619-627. doi:10.1111/j.1442-2042.2004.00860.x
Yamada Y, Sakamoto S, Sazuka T, et al. Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men. Int J Urol. 2016;23(1):49-54. doi:10.1111/iju.12952
Mitsuzuka K, Narita S, Koie T, et al. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. BJU Int. 2013;111(6):914-920. doi:10.1111/j.1464-410X.2012.11658.x
Frankcombe DE, Li J, Cohen RJ. Redefining the concept of clinically insignificant prostate cancer. Urology. 2020;136:176-179. doi:10.1016/j.urology.2019.10.019
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244-252. doi:10.1097/pas.0000000000000530
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106-119. doi:10.1016/j.eururo.2016.02.028
Kato M, Kimura K, Hirakawa A, et al. Prognostic parameter for high risk prostate cancer patients at initial presentation. Prostate. 2018;78(1):11-16. doi:10.1002/pros.23438
Kato M, Hirakawa A, Kobayashi Y, et al. The influence of the presence of intraductal carcinoma of the prostate on the Grade Group system's prognostic performance. Prostate. 2019;79(10):1065-1070. doi:10.1002/pros.23818
Porter LH, Lawrence MG, Ilic D, et al. Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur Urol. 2017;72(4):492-495. doi:10.1016/j.eururo.2017.03.013
Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol. 2010;184(4):1328-1333. doi:10.1016/j.juro.2010.06.017
Kweldam CF, Kümmerlin IP, Nieboer D, et al. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol. 2016;29(6):630-636. doi:10.1038/modpathol.2016.49
van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020;44(8):e87-e99. doi:10.1097/pas.0000000000001497
Chua MLK, Lo W, Pintilie M, et al. A prostate cancer “Nimbosus”: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies. Eur Urol. 2017;72(5):665-674. doi:10.1016/j.eururo.2017.04.034
Böttcher R, Kweldam CF, Livingstone J, et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer. 2018;18(1):8. doi:10.1186/s12885-017-3976-z
Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol. 2019;75(3):378-382. doi:10.1016/j.eururo.2018.10.009
Bettendorf O, Schmidt H, Staebler A, et al. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer. 2008;47(7):565-572. doi:10.1002/gcc.20560
Shah RB, Shore KT, Yoon J, Mendrinos S, McKenney JK, Tian W. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). Prostate. 2019;79(11):1267-1273. doi:10.1002/pros.23831
Tsuzuki T. Intraductal carcinoma of the prostate: a comprehensive and updated review. Int J Urol. 2015;22(2):140-145. doi:10.1111/iju.12657
Zhao J, Sun G, Zhu S, et al. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. BJU Int. 2021;129:345-355. doi:10.1111/bju.15530
Ploussard G, Epstein JI, Montironi R, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011;60(2):291-303. doi:10.1016/j.eururo.2011.05.006
Kimura K, Tsuzuki T, Kato M, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate. 2014;74(6):680-687. doi:10.1002/pros.22786
Zhao J, Sun G, Liao B, et al. Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer. BJU Int. 2018;122(6):994-1002. doi:10.1111/bju.14398
Kench JG, Amin MB, Berney DM, et al. WHO classification of tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology. 2022;81(4):447-458.
Ericson KJ, Wu SS, Lundy SD, Thomas LJ, Klein EA, McKenney JK. Diagnostic accuracy of prostate biopsy for detecting cribriform Gleason pattern 4 carcinoma and intraductal carcinoma in paired radical prostatectomy specimens: implications for active surveillance. J Urol. 2020;203(2):311-319. doi:10.1097/ju.0000000000000526
Ochiai A, Troncoso P, Chen ME, Lloreta J, Babaian RJ. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol. 2005;174(6):2164-2168. doi:10.1097/01.ju.0000181211.49267.43
Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000;163(1):174-178.
Ellis CL, Walsh PC, Partin AW, Epstein JI. Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU Int. 2013;111(8):E306-E309. doi:10.1111/j.1464-410X.2012.11680.x
Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178(6):2359-2365. doi:10.1016/j.juro.2007.08.039
van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007;52(6):1560-1563. doi:10.1016/j.eururo.2007.05.011
Kakehi Y, Kamoto T, Shiraishi T, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol. 2008;38(2):122-128. doi:10.1093/jjco/hym161
Schiffmann J, Connan J, Salomon G, et al. Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. Prostate. 2015;75(1):45-49. doi:10.1002/pros.22889
Kryvenko ON, Epstein JI. Definition of insignificant tumor volume of Gleason score 3 + 3 = 6 (Grade Group 1) prostate cancer at radical prostatectomy-is it time to increase the threshold. J Urol. 2016;196(6):1664-1669. doi:10.1016/j.juro.2016.06.013
Meyer CP, Hansen J, Boehm K, et al. Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World J Urol. 2017;35(2):199-206. doi:10.1007/s00345-016-1861-z
McNeal JE, Yemoto CEM. Spread of adenocarcinoma within prostatic ducts and acini. morphologic and clinical correlations. Am J Surg Pathol. 1996;20(7):802-814. doi:10.1097/00000478-199607000-00003
Cohen RJ, McNeal JE, Baillie T. Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression. Prostate. 2000;43(1):11-19. doi:10.1002/(sici)1097-0045(20000401)43:1<11::aid-pros3>3.0.co;2-b
Samaratunga H, Delahunt B, Gianduzzo T, et al. The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology. 2015;47(6):515-519. doi:10.1097/pat.0000000000000315
Offermann A, Hupe MC, Sailer V, Merseburger AS, Perner S. The new ISUP 2014/WHO 2016 prostate cancer Grade Group system: first resume 5 years after introduction and systemic review of the literature. World J Urol. 2020;38(3):657-662. doi:10.1007/s00345-019-02744-4